The Enhanced Games, a high-profile sports event that allowed athletes to compete while using performance-enhancing drugs, failed to deliver on both its competitive and financial promises. Launched by the telehealth company Enhanced Group and backed by notable figures like Peter Thiel, the games attracted significant attention for challenging traditional sports doping rules. However, despite promises of transformation, the May event in Las Vegas featured only one world record and lacked the excitement anticipated by fans and insiders alike.

Financially, the company behind the event posted a $62 million loss in the second quarter, largely due to the costs associated with hosting the games. Enhanced Group, which went public earlier this year with a $1.2 billion valuation, relies primarily on its core telehealth platform that offers FDA-approved treatments such as peptides and testosterone injections. Yet, in the recent quarter, most revenue was tied to sponsorship deals related to the games, rather than the company’s health product sales, raising questions about the sustainability of its business model.

The company’s recent report suggests that the original vision of hosting annual Enhanced Games events may be in doubt unless the business can significantly boost income or absorb ongoing losses. To maintain engagement and manage costs, Enhanced Group has introduced a lower-budget online competition series called Enhanced Breakers, intended to provide year-round visibility for athletes, sponsors, and performance medicine without the high expenses of full-scale Games events.

Despite the struggle of Enhanced Group, the broader market for peptides and related performance-enhancing substances is thriving. Fueled by recent FDA reclassifications and regulatory shifts, the peptide industry is growing rapidly, particularly in Silicon Valley where startups are driving biohacking trends. However, this growth is outpacing regulation, with concerns about the industry’s oversight persisting amid the rising influence of figures like Robert F. Kennedy Jr. and an evolving health policy landscape.